Abhijit Mazumder
Overview
Explore the profile of Abhijit Mazumder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
589
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Telesco S, Brodmerkel C, Zhang H, Kim L, Johanns J, Mazumder A, et al.
Gastroenterology
. 2018 Jul;
155(4):1008-1011.e8.
PMID: 29981298
Golimumab, a tumor necrosis factor antagonist, is an effective treatment for patients with moderate-to-severe ulcerative colitis (UC); however, more than 50% of initial responders lose their response to the drug...
2.
Mazumder A, Wang Y, Godsey J
Per Med
. 2018 May;
3(3):299-310.
PMID: 29788655
Many of the techniques that are employed today by pathologists and oncologists to generate a diagnosis, prognosis or prediction of response have not changed over several decades. However, new molecular...
3.
Mazumder A, Khare N, Govil P
Int Sch Res Notices
. 2016 Jul;
2014:621479.
PMID: 27379333
18 surface sediment samples collected from a north-south transect along the Indian Ocean have been analyzed for planktonic Foraminifera content. Among the other planktonic foraminiferal faunas, Globigerina bulloides was present...
4.
Sethi K, Sarkar S, Das S, Rajput S, Mazumder A, Roy B, et al.
J Exp Ther Oncol
. 2011 Nov;
9(3):187-99.
PMID: 22070050
Immunohistochemical markers have been proposed for thyroid cancer diagnosis and prognostic studies. Immunohistochemical analysis of CK-19, NF-kappaB, beta-catenin, E-cadherin and EGFR were done to evaluate their diagnostic and prognostic efficiencies...
5.
Trusheim M, Burgess B, Hu S, Long T, Averbuch S, Flynn A, et al.
Nat Rev Drug Discov
. 2011 Nov;
10(11):817-33.
PMID: 22037040
Co-developing a drug with a diagnostic to create a stratified medicine - a therapy that is targeted to a specific patient population on the basis of a clinical characteristic such...
6.
Jiang Y, Casey G, Lavery I, Zhang Y, Talantov D, Martin-McGreevy M, et al.
J Mol Diagn
. 2008 Jun;
10(4):346-54.
PMID: 18556775
The 5-year survival rate for patients with Stage II colon cancer is approximately 75%. However, there is no clinical test available to identify the 25% of patients at high risk...
7.
Mazumder A, Palma A, Wang Y
Expert Rev Mol Diagn
. 2008 Mar;
8(2):125-8.
PMID: 18366298
No abstract available.
8.
Vener T, Derecho C, Baden J, Wang H, Rajpurohit Y, Skelton J, et al.
Clin Chem
. 2008 Mar;
54(5):874-82.
PMID: 18339699
Background: Several studies have demonstrated the value of DNA methylation in urine-based assays for prostate cancer diagnosis. However, a multicenter validation with a clinical prototype has not been published. Methods:...
9.
Mehrotra J, Varde S, Wang H, Chiu H, Vargo J, Gray K, et al.
Prostate
. 2007 Dec;
68(2):152-60.
PMID: 18058812
Background: Although a field effect in which transformed cells extend beyond morphologically evident tumor has been proposed in cancer, little direct evidence exists as to its magnitude and spatial resolution....
10.
Mazumder A, Wang Y
Pharmacogenomics
. 2006 Dec;
7(8):1167-73.
PMID: 17184204
The advent of DNA microarray technologies has enabled the development of gene expression signatures that can be used for prognostic and predictive purposes. This new information can change the paradigm...